A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Conditions
- Non-Small-Cell Lung Cancer
Interventions
- DRUG: Zoledronic acid 4 mg
Sponsor
Novartis Pharmaceuticals